Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
about
Notch Signaling in Neuroendocrine TumorsNotch3 and Mef2c proteins are mutually antagonistic via Mkp1 protein and miR-1/206 microRNAs in differentiating myoblastsHyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcomaPharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMSExpression of notch family proteins in placentas from patients with early-onset severe preeclampsia.TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.New therapeutic targets in soft tissue sarcoma.Notch inhibitors for cancer treatment.Notch signaling in pediatric soft tissue sarcomasAlternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiationHistone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1β.Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cellsPAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.Cyclin D1 is a major target of miR-206 in cell differentiation and transformation.Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma.Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.Glycogen synthase kinase 3β represses MYOGENIN function in alveolar rhabdomyosarcoma.The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.Involvement of α2-antiplasmin in dendritic growth of hippocampal neurons.Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
P2860
Q26752380-3BBA0616-17D4-4868-85C9-46A547AD353EQ30416251-663DDB7B-EF1D-467E-804B-2D59F198CD55Q33567866-D3B5BB22-7DA4-4D2C-A1B2-A340644717DFQ33586736-1CC0D07A-321A-486C-9FEF-DC305BECD54BQ33592489-366F75D9-C2AD-4C7C-98D1-76DE3DF487B1Q33593474-910709A1-6BA5-4520-9A15-D37958337C21Q33734818-9009F26F-47F1-4A71-A3E5-DA0359319B97Q34267924-2A3E8C72-1FAC-4520-80B4-13539C54BCA7Q34330869-4058E7EC-E0F8-4CF3-A077-761C8B1E36B4Q34480012-B0377162-2965-40A5-A012-5EFAA3B15BA9Q34801443-3E5C5EB2-B923-4D19-B7DD-EF6170A4F913Q35828593-964D1775-8072-4734-9E35-B1BB83122626Q35861006-66B13E02-5FC5-4568-A3B2-2F5CC2ABABA4Q35922940-DC22084E-199A-4B79-A2C4-A4074C1D21D7Q36685371-AA5FFFA4-CB6A-4DDB-AA66-BE0434898A4BQ37427738-B8A2350F-6BEC-4C04-AE00-6DCCED14846FQ37482775-681D2FAF-A6C5-40BB-B471-A2A530195FD8Q37525842-92836FE9-41F3-43C6-BEE7-708F6B6CEE68Q37702007-844872B8-8ED2-4213-8213-40F03A8E0C78Q38045441-7910689A-E8B9-493F-9CBE-7B3328E4CF74Q38105879-CF6C588C-C784-4229-912D-E32471CAF382Q38781419-4C59A395-F7CD-4F2E-A8F2-7FF28B925232Q39020234-36CC9172-86AF-4AC1-BE90-47999D4FD63FQ39064876-8FC2BE5A-BA62-43AA-BA8B-F8E956AE05A9Q39144774-75576A44-43B1-40AD-974C-4F1061268B24Q47782462-742428DB-DC4F-47EB-A411-D10104C95F13Q47848908-7EF6CF99-5D0B-404D-B740-F933C8B2E6C9Q51017591-A6A5D13F-AD16-499B-AD46-C5B5E5B3D0CAQ51599875-FB32DDDE-B50E-481C-883C-7E6C3276D578
P2860
Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Inhibition of Notch3 signallin ...... l growth in vitro and in vivo.
@ast
Inhibition of Notch3 signallin ...... l growth in vitro and in vivo.
@en
type
label
Inhibition of Notch3 signallin ...... l growth in vitro and in vivo.
@ast
Inhibition of Notch3 signallin ...... l growth in vitro and in vivo.
@en
prefLabel
Inhibition of Notch3 signallin ...... l growth in vitro and in vivo.
@ast
Inhibition of Notch3 signallin ...... l growth in vitro and in vivo.
@en
P2093
P2860
P50
P356
P1476
Inhibition of Notch3 signallin ...... ll growth in vitro and in vivo
@en
P2093
F Locatelli
M De Salvo
M Locatelli
N Carlesso
R Ciarapica
P2860
P2888
P304
P356
10.1038/CDD.2011.171
P577
2011-11-25T00:00:00Z